April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Restoring Visual Function in Adult Rd1 Mice Using Virally-Delivered Channelrhodopsin
Author Affiliations & Notes
  • A. Horsager
    Eos Neuroscience, Inc., Los Angeles, California
    Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, California
  • J. Liu
    Ophthalmology, University of Florida, Gainesville, Florida
  • E. S. Boyden
    Eos Neuroscience, Inc., Los Angeles, California
    MIT Media Lab, Massachusetts Institute of technology, Boston, Massachusetts
  • A. C. Arman
    Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, California
  • B. C. Matteo
    Eos Neuroscience, Inc., Los Angeles, California
  • A. P. Sampath
    Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, California
  • W. W. Hauswirth
    Ophthalmology, University of Florida, Gainesville, Florida
  • Footnotes
    Commercial Relationships  A. Horsager, Eos Neuroscience, Inc., E; Patents, P; J. Liu, None; E.S. Boyden, Eos Neuroscience, Inc., E; Patents, P; A.C. Arman, None; B.C. Matteo, Eos Neuroscience, Inc., E; Patents, P; A.P. Sampath, None; W.W. Hauswirth, AGTC, Inc., E; Patents, P.
  • Footnotes
    Support  EY11123, EY13729, EY07132, NS36302, FFB, MVRF, Eos Neuroscience, Inc.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 3898. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Horsager, J. Liu, E. S. Boyden, A. C. Arman, B. C. Matteo, A. P. Sampath, W. W. Hauswirth; Restoring Visual Function in Adult Rd1 Mice Using Virally-Delivered Channelrhodopsin. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3898.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Channelrhodopsin (ChR2) is a light-sensitive protein that, when expressed in mammalian neurons, depolarizes the tissue in response to light activation. Using cell type-specific promoters, expression of ChR2 can be genetically-targeted so as to activate specific neural circuits. We show that behavioral and physiological visual function is restored in the adult rd1 mouse when ChR2 expression is genetically-targeted to the ON bipolar cells using the GRM6 promoter, and delivered using an adeno-associated virus (AAV).

Methods: : We evaluated retinal bipolar cell transduction using wild-type and capsid-mutated AAV serotypes. Vector, including the ChR2 and green fluorescent protein (GFP) genes, was either subretinally or intravitreally injected in two month old rd1 mice under the control of the CBA or GRM6 promoter. GFP expression and localization was evaluated using confocal microscopy coupled with immunohistochemistry 2 weeks later. Next, visual function was measured in wild-type, rd1 untreated, and rd1 ChR2-treated mice using the Morris water maze, and through in vitro retinal patch clamp recordings.

Results: : Two wild-type serotypes were effective at transducing retinal bipolar cells. However, capsid-mutated serotypes were able to increase bipolar cell transduction by as much as 20-fold, even with an intravitreal injection. In the water maze task, the ChR2-treated mice learned the task nearly as well as the wild-type mice (the rd1 untreated mice did not learn the task). Bipolar and ganglion cells recordings show that depolarization in these cells can be mediated by ChR2 activation.

Conclusions: : Expression of ChR2 in ON bipolar cells, delivered using AAV in adult rd1 mice that have lost nearly all photoreceptors, restores behavioral and physiological function. Equally as important, it is possible to target ChR2 expression to bipolar cells using a capsid-mutated AAV, even with an intravitreal injection. Further research is necessary to evaluate perceptual threshold and visual acuity in these treated animals.

Keywords: gene transfer/gene therapy • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×